Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Medical Conditions

Kidney Diseases
Renal Insufficiency, Chronic
Cardiovascular Diseases
Atherosclerosis


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2024 Feb 2029

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Retatrutide;

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University Hospital Coventry & Warwickshire
    Coventry
    CV2 2DX
  • Ipswich Hospital
    Ipswich
    Suffolk
    IP4 5PD
  • Royal London Hospital
    London
    England
    E1 1BB
  • Newquay Health Centre
    Newquay
    Cornwall
    TR7 1RU
  • Musgrove Park Hospital
    Taunton
    Somerset
    TA1 5DA
  • Homecroft Surgery
    Redruth
    Cornwall
    TR16 4ET
  • FutureMeds - Birmingham
    Birmingham
    B21 9RY
  • Swansea University
    Swansea
    Swansea [Abertawe Gb-ata]
    SA2 8PP
  • FutureMeds - Liverpool
    Bromborough
    Wirral
    CH62 6EE
  • Hull Royal Infirmary
    Hull
    Kingston Upon Hull
    HU3 2JZ
  • Rame Group Practice
    Torpoint
    Cornwall
    PL11 2TB
  • FutureMeds Glasgow - CPS Research
    Glasgow
    Glasgow City
    G20 7BE
  • Futuremeds-Newcastle
    Newcastle
    England
    NE6 1SG
  • FutureMeds Teesside - Middlefield Centre
    Stockton-on-Tees
    TS19 8PE
  • Aberdeen Royal Infirmary
    Aberdeen
    Aberdeen City
    AB25 2ZN
  • Moorgreen Hospital
    West End
    England
    SO30 3JB
  • Altnagelvin Area Hospital
    Londonderry
    London, City Of
    BT47 6SB
  • Ashton Medical Group - Chapel House
    Lancashire
    OL6 6EW

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com



The study is sponsored by Eli Lilly and Company





We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06383390
Last updated 22 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.